Record TRCV and major contract shape NRC (NRC) Q1 2026 results
Rhea-AI Filing Summary
NRC Health reported first-quarter 2026 results with revenue of $34.8 million, up from $33.6 million a year earlier, marking its first year-over-year revenue growth since 2023. Net income declined to $3.2 million from $5.8 million, and diluted earnings per share fell to $0.14 from $0.25.
Total Recurring Contract Value rose 13% year-over-year to $152.1 million, and cash flow from operations increased 8% to $7.2 million, driving free cash flow of $5.3 million. The company highlighted signing the largest deal in its 45-year history and declared a quarterly dividend of $0.16 per share, payable July 10, 2026, to shareholders of record on June 26, 2026.
Positive
- None.
Negative
- None.
Insights
Revenue returned to growth, but profitability and margins weakened while cash generation improved.
NRC Health delivered Q1 2026 revenue of $34.8M, up slightly from $33.6M, its first year-over-year increase since 2023. Management also reported a 13% rise in Total Recurring Contract Value to $152.1M, suggesting a stronger contracted backlog.
Profitability softened: net income dropped to $3.2M from $5.8M, and Adjusted EBITDA slipped to $9.4M with margin compressing from 30.8% to 27.0%. Higher selling, general, and administrative expenses appear to be pressuring margins even as revenue edges higher.
On the cash side, operating cash flow rose to $7.2M and free cash flow improved to $5.3M, aided by lower capital expenditures. The board maintained a quarterly dividend of $0.16 per share, which, together with ongoing share repurchases, returns capital while the company invests in growth.
8-K Event Classification
Key Figures
Key Terms
Total Recurring Contract Value financial
Adjusted EBITDA financial
Free Cash Flow financial
forward-looking statements regulatory
Earnings Snapshot
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
||
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
|
|
||
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
|
|
||
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
EXHIBIT
NUMBER
|
EXHIBIT DESCRIPTION
|
|
99.1
|
NRC Health press release announcing its financial and operating results for the first quarter ended March 31, 2026.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
|
NRC HEALTH
|
||
|
(Registrant)
|
||
|
Date: April 28, 2026
|
By:
|
/s/ Shane Harrison
|
|
Shane Harrison
|
||
|
Executive Vice President and Chief Financial Officer
|
||
Exhibit 99.1
 |
1245 Q Street, Lincoln, NE 68508 P: 1 800 388 4264 | F: 402 475 9061 nrchealth.com |
NRC HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
First quarter TRCV* increased 13% year-over-year to $152.1 million
Cash flow from operations increased 8% year-over-year to $7.2 million
LINCOLN, Nebraska, April 28, 2026 —NRC Health (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the first quarter 2026.
"We delivered a strong start to 2026, with record Total Recurring Contract Value and our first quarter of year-over-year revenue growth since 2023, reflecting the tangible momentum building across our business,” said Trent Green, CEO of NRC Health. “The signing of the largest deal in our 45-year history is a powerful validation of our strategy and the differentiated value we deliver to health systems navigating an increasingly complex environment. Our new sales and customer retention both reached multi-year highs this quarter, underscoring the trust our customers place in us. As we look ahead, we remain committed to evolving from a measurement partner to a true outcomes driver, helping healthcare organizations turn Human Understanding into measurable, repeatable improvement."
First Quarter 2026 Highlights
|
● |
Revenue: Total revenue was $34.8 million for the three months ended March 31, 2026, up 4% from the prior year |
|
● |
Net Income: GAAP net income was $3.2 million, representing 9% of revenue, and Adjusted Net Income* was $4.6 million, representing 13% of revenue |
|
● |
Adjusted EBITDA: Adjusted EBITDA* was $9.4 million, representing 27% of revenue |
|
● |
Earnings Per Share: GAAP net income per fully diluted share was $0.14 on 21.9 million fully diluted shares; Adjusted net income per diluted share* was $0.21 on 21.9 million fully diluted shares |
|
● |
Cash Flow: Net cash flow from operating activities was $7.2 million, representing 21% of revenue; Free cash flow* was $5.4 million, representing 15% of revenue |
|
● |
TRCV: Total Recurring Contract Value (TRCV)* was $152.1 million, up 13% year-over-year, and grew sequentially for the sixth consecutive quarter |
* These financial measures are defined below under the headings “Non-GAAP Financial Measures” and “Total Recurring Contract Value.” Reconciliations of the non-GAAP measures to their most closely comparable GAAP measures are included in the tables in this release.
NRC Health Announces First Quarter 2026 Results
Page 2
April 28, 2026
Dividend Declaration
The Company’s Board of Directors on April 15, 2026, declared a quarterly cash dividend of $0.16 per share. The dividend will be payable on Friday, July 10, 2026, to shareholders of record as of the close of business on Friday, June 26, 2026.
Earnings Call Information
The company will be hosting a conference call to discuss the financial results on Tuesday, April 28, 2026, at 4:30 p.m. ET. A live webcast and replay of the call will be available on the NRC Health Investor Relations website at nrchealth.com/investor-relations.
About NRC Health
For more than 45 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
Total Recurring Contract Value
Total Recurring Contract Value, or TRCV, is viewed by management as a leading indicator of our future revenue trends. It represents the total annualized contract value under customer contracts that are in effect or contractually committed as of the most recent quarter-end, based on contractual pricing and term provisions, and expected to be in force over the subsequent 12 months. TRCV is an operating metric and is not a measure of revenue recognized under U.S. GAAP.
Non-GAAP Financial Measures
In addition to consolidated GAAP financial measures, NRC Health reviews various non-GAAP financial measures that management believes to be important in the evaluation of its operating results and performance, including “Adjusted Net Income,” “Adjusted Earnings per Share,” “Adjusted EBITDA,” “Adjusted EBITDA Margin,” “Free Cash Flow,” and “Free Cash Flow Margin.” Reconciliations of GAAP to non-GAAP financial information are provided later in this release.
NRC Health believes Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, and Free Cash Flow Margin are helpful supplemental measures to assist management and investors in evaluating the Company’s operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of NRC Health’s business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility. Adjusted Net Income represents net income adjusted to add back certain management bonuses and non-cash stock compensation and the related tax. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization, certain management bonuses, and non-cash stock compensation items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by our revenue.
NRC Health Announces First Quarter 2026 Results
Page 3
April 28, 2026
NRC Health considers Free Cash Flow to be a measure that provides useful information to management and investors about our liquidity. Free Cash Flow does not represent residual cash flow available for discretionary expenditures. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. Free Cash Flow Margin represents Free Cash Flow divided by our revenue.
There is no comprehensive, authoritative guidance for the presentation of such non-GAAP information, which is only meant to supplement GAAP results by providing additional information that management utilizes to assess performance.
Forward-Looking Statements
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” “focus,” “potential,” “will,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2025, and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
Media Contact
marketing@nrchealth.com
Investor Contact
ir@nrchealth.com
NRC Health Announces First Quarter 2026 Results
Page 4
April 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Income
(In thousands except per share data, unaudited)
|
Three months ended |
||||||||
|
2026 |
2025 |
|||||||
|
Revenue |
$ | 34,803 | $ | 33,551 | ||||
|
Operating expenses: |
||||||||
|
Direct |
13,646 | 13,057 | ||||||
|
Selling, general, and administrative |
13,419 | 10,356 | ||||||
|
Depreciation and amortization |
2,169 | 1,542 | ||||||
|
Total operating expenses |
29,234 | 24,955 | ||||||
|
Operating income |
5,569 | 8,596 | ||||||
|
Other income (expense): |
||||||||
|
Interest income |
35 | 19 | ||||||
|
Interest expense |
(1,255 | ) | (899 | ) | ||||
|
Other, net |
30 | 7 | ||||||
|
Total other expense |
(1,190 | ) | (873 | ) | ||||
|
Income before income taxes |
4,379 | 7,723 | ||||||
|
Provision for income taxes |
1,157 | 1,936 | ||||||
|
Net income |
$ | 3,222 | $ | 5,787 | ||||
|
Earnings per share of common stock: |
||||||||
|
Basic |
$ | 0.14 | $ | 0.25 | ||||
|
Diluted |
$ | 0.14 | $ | 0.25 | ||||
|
Weighted average shares and share equivalents outstanding: |
||||||||
|
Basic |
21,799 | 22,972 | ||||||
|
Diluted |
21,911 | 22,974 | ||||||
NRC Health Announces First Quarter 2026 Results
Page 5
April 28, 2026
NRC HEALTH
Condensed Consolidated Balance Sheets
(Dollars in thousands except share amounts and par value)
|
March 31, 2026 |
December 31, 2025 |
|||||||
|
(unaudited) |
||||||||
|
Assets |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | 2,547 | $ | 4,139 | ||||
|
Accounts receivable, net |
10,833 | 11,108 | ||||||
|
Other current assets |
6,604 | 4,962 | ||||||
|
Total current assets |
19,984 | 20,209 | ||||||
|
Property and equipment, net |
40,305 | 40,474 | ||||||
|
Goodwill |
66,152 | 66,152 | ||||||
|
Other, net |
8,118 | 8,043 | ||||||
|
Total assets |
$ | 134,559 | $ | 134,878 | ||||
|
Liabilities and Shareholders’ Equity |
||||||||
|
Current liabilities: |
||||||||
|
Current portion of notes payable, net of unamortized debt issuance costs |
$ | 4,015 | $ | 4,014 | ||||
|
Accounts payable and accrued expenses |
4,809 | 4,066 | ||||||
|
Accrued wages and bonuses |
6,603 | 7,218 | ||||||
|
Deferred revenue |
17,192 | 16,201 | ||||||
|
Dividends payable |
3,606 | 3,625 | ||||||
|
Other current liabilities |
2,245 | 1,496 | ||||||
|
Total current liabilities |
38,470 | 36,620 | ||||||
|
Notes payable, net of current portion and unamortized debt issuance costs |
74,017 | 75,021 | ||||||
|
Other non-current liabilities |
8,577 | 9,247 | ||||||
|
Total liabilities |
121,064 | 120,888 | ||||||
|
Shareholders’ equity: |
||||||||
|
Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued |
- | - | ||||||
|
Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,975,649 in 2026 and 31,966,504 in 2025, outstanding 22,536,696 in 2026 and 22,637,252 in 2025 |
32 | 32 | ||||||
|
Additional paid-in capital |
185,627 | 183,880 | ||||||
|
Retained earnings (accumulated deficit) |
(17,682 | ) | (17,298 | ) | ||||
|
Treasury stock |
(154,482 | ) | (152,624 | ) | ||||
|
Total shareholders’ equity |
$ | 13,495 | $ | 13,990 | ||||
|
Total liabilities and shareholders’ equity |
$ | 134,559 | $ | 134,878 | ||||
NRC Health Announces First Quarter 2026 Results
Page 6
April 28, 2026
NRC HEALTH
Condensed Consolidated Statements of Cash Flows
(In thousands, unaudited)
|
Three months ended |
||||||||
|
March 31, |
||||||||
|
2026 |
2025 |
|||||||
|
Cash flows from operating activities: |
||||||||
|
Net income |
$ | 3,222 | $ | 5,787 | ||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation and amortization |
2,169 | 1,542 | ||||||
|
Deferred income tax expense |
(36 | ) | 1,860 | |||||
|
Reserve for uncertain tax positions |
(56 | ) | 76 | |||||
|
Non-cash share-based compensation expense |
1,608 | 171 | ||||||
|
Change in fair value of contingent consideration |
- | 31 | ||||||
|
Loss on extinguishment of debt |
- | 67 | ||||||
|
Amortization of debt issuance costs |
27 | 15 | ||||||
|
Net changes in assets and liabilities: |
||||||||
|
Trade accounts receivable |
275 | (272 | ) | |||||
|
Prepaid expenses and other current and long-term assets |
(1,627 | ) | (2,419 | ) | ||||
|
Deferred contract costs, net |
(625 | ) | 24 | |||||
|
Operating lease assets and liabilities, net |
(30 | ) | (26 | ) | ||||
|
Accounts payable |
942 | 627 | ||||||
|
Accrued expenses, wages, and bonuses |
(889 | ) | (472 | ) | ||||
|
Income taxes receivable and payable |
1,265 | (80 | ) | |||||
|
Deferred revenue |
935 | (285 | ) | |||||
|
Net cash provided by operating activities |
7,180 | 6,646 | ||||||
|
Cash flows from investing activities: |
||||||||
|
Capital expenditures |
(1,834 | ) | (2,986 | ) | ||||
|
Net cash used in investing activities |
(1,834 | ) | (2,986 | ) | ||||
|
Cash flows from financing activities: |
||||||||
|
Borrowings on notes payable |
- | 27,738 | ||||||
|
Payments on notes payable |
(1,030 | ) | (28,724 | ) | ||||
|
Borrowings on revolving loan |
2,500 | 8,000 | ||||||
|
Payments on revolving loan |
(2,500 | ) | (4,503 | ) | ||||
|
Payment of debt issuance costs |
- | (62 | ) | |||||
|
Payments on finance lease obligations |
(3 | ) | (2 | ) | ||||
|
Proceeds from the exercise of share-based awards |
139 | 132 | ||||||
|
Payment of acquisition contingent consideration |
(484 | ) | (280 | ) | ||||
|
Repurchase of shares for treasury |
(1,935 | ) | (4,920 | ) | ||||
|
Payment of dividends on common stock |
(3,625 | ) | (2,770 | ) | ||||
|
Net cash used in financing activities |
(6,938 | ) | (5,391 | ) | ||||
|
Change in cash and cash equivalents |
(1,592 | ) | (1,731 | ) | ||||
|
Cash and cash equivalents at beginning of period |
4,139 | 4,233 | ||||||
|
Cash and cash equivalents at end of period |
$ | 2,547 | $ | 2,502 | ||||
NRC Health Announces First Quarter 2026 Results
Page 7
April 28, 2026
NRC HEALTH
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share data, unaudited)
Adjusted Net Income and Adjusted Earnings per Share
|
Three months ended March 31, |
||||||||
|
2026 |
2025 |
|||||||
|
Net income |
$ | 3,222 | $ | 5,787 | ||||
|
Add back: |
||||||||
|
Non-cash stock compensation |
1,608 | 171 | ||||||
|
Tax on stock compensation |
(262 | ) | (43 | ) | ||||
|
Adjusted net income |
$ | 4,568 | $ | 5,915 | ||||
|
Weighted average shares and share equivalents outstanding, diluted |
21,911 | 22,974 | ||||||
|
Adjusted earnings per share, diluted |
$ | 0.21 | $ | 0.26 | ||||
Adjusted EBITDA and Adjusted EBITDA Margin
|
Three months ended March 31, |
||||||||
|
2026 |
2025 |
|||||||
|
Net income |
$ | 3,222 | $ | 5,787 | ||||
|
Add back: |
||||||||
|
Depreciation and amortization |
2,169 | 1,542 | ||||||
|
Interest expense |
1,255 | 899 | ||||||
|
Income taxes |
1,157 | 1,936 | ||||||
|
Non-cash stock compensation |
1,608 | 171 | ||||||
|
Adjusted EBITDA |
$ | 9,411 | $ | 10,335 | ||||
|
Adjusted EBITDA margin |
27.0 | % | 30.8 | % | ||||
Free Cash Flow and Free Cash Flow Margin
|
Three months ended March 31, |
||||||||
|
2026 |
2025 |
|||||||
|
Net cash provided by operating activities |
$ | 7,180 | $ | 6,646 | ||||
|
Less: |
||||||||
|
Capital expenditures |
1,834 | 2,986 | ||||||
|
Free cash flow |
$ | 5,346 | $ | 3,660 | ||||
|
Free cash flow margin |
15.4 | % | 10.9 | % | ||||